Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25548688 | 0.87 | CYP2C9 (0.70) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL6589989 | 0.85 | CYP11B1 (0.53) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL7580210 | 0.85 | ENPP1 (0.65) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL25548998 | 0.85 | ENPP1 (0.65) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL28917141 | 0.85 | ENPP1 (0.62) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL24000595 | 0.85 | ENPP1 (0.69) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL30088725 | 0.84 | ENPP1 (0.67) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL24000743 | 0.84 | ENPP1 (0.74) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL30088793 | 0.83 | ENPP1 (0.73) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL7515428 | 0.82 | ENPP1 (0.47) | ENPP1CYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1097142-B1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-10-13 | — | — | EP | disclosed |
| EP-1124829-B1 | TRICYCLIC PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-08-04 | — | — | EP | disclosed |
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | ZAMBON GROUP S.P.A | 2004-03-04 | — | — | US | disclosed |
| EP-1042300-B1 | PHTHALAZINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-02-11 | — | — | EP | disclosed |
| EP-1371648-A1 | Phthalazine derivatives phosphodiesterase 4 inhibitors | ZAMBON GROUP S.p.A. (IT) | 2003-12-17 | — | — | EP | disclosed |
| US-6589951-B1 | N right-arrowO derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF pharmaceutically acceptable salt thereof are PDE 4 and TNF alpha inhibitors. | ZAMBON GROUP S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
| US-6525055-B1 | Allergic and inflammatory pathologies such as, for example, emphysema, chronic bronchitis, asthma and allergic rhinitis. | ZAMBON GROUP S.P.A. (IT) | 2003-02-25 | — | — | US | disclosed |
| US-6498160-B2 | FOR THERAPY OF EMPHYSEMA, CHRONIC BRONCHITIS, ASTHMA AND ALLERGIC RHINITIS | ZAMBON GROUP S.P.A. (IT) | 2002-12-24 | — | — | US | disclosed |
| US-6492360-B1 | Phthalazine derivatives phosphodiesterase 4 inhibitors | ZAMBON GROUP S.P.A. (IT) | 2002-12-10 | — | — | US | disclosed |
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | ZAMBON GROUP S.P.A. (IT) | 2002-05-16 | — | — | US | disclosed |
| US-6340684-B1 | TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, ALLERGIC RHINITIS | ZAMBON GROUP S.P.A. (IT) | 2002-01-22 | — | — | US | disclosed |
| US-6329370-B1 | CARDIOVASCULAR DISORDERS AND TUMOR NECROSIS FACTOR (HEREINAFTER TNF.SUB..ALPHA.), A CYTOKINE WITH PRO-INFLAMMATORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2001-12-11 | — | — | US | disclosed |
| EP-1098886-A1 | PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-05-16 | — | — | EP | disclosed |
| EP-1097142-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-05-09 | — | — | EP | disclosed |
| EP-1042300-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000005218-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-02-03 | — | — | WO | disclosed |
| WO-2000005219-A1 | PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999032456-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | ENPP1 53/4885CYP3A4 186/4885CYP2C9 1196/4885 |
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | PDE5A, PDE3B, PDE3A | ENPP1 218/4885CYP3A4 66/4885CYP2C9 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.